Chugai Pharmaceutical Co. Ltd. has signed a collaboration agreement with GSK plc’s Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody. Under this agreement, GSK GH will perform activities and explore potential funding for the initiation of clinical studies of AID-351.